Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Database
Language
Document Type
Year range
1.
J Neurol ; 269(9): 4581-4603, 2022 Sep.
Article in English | MEDLINE | ID: covidwho-1971704

ABSTRACT

The SARS-CoV-2 pandemic has raised particular concern for people with Multiple Sclerosis, as these people are believed to be at increased risk of infection, especially those being treated with disease-modifying therapies. Therefore, the objective of this review was to describe how COVID-19 affects people who suffer from Multiple Sclerosis, evaluating the risk they have of suffering an infection by this virus, according to the therapy to which they are subjected as well as the immune response of these patients both to infection and vaccines and the neurological consequences that the virus can have in the long term. The results regarding the increased risk of infection due to treatment are contradictory. B-cell depletion therapies may cause patients to have a lower probability of generating a detectable neutralizing antibody titer. However, more studies are needed to help understand how this virus works, paying special attention to long COVID and the neurological symptoms that it causes.


Subject(s)
COVID-19 , Multiple Sclerosis , Antibodies, Viral , COVID-19/complications , COVID-19 Vaccines/adverse effects , Humans , Multiple Sclerosis/complications , Multiple Sclerosis/therapy , SARS-CoV-2 , Post-Acute COVID-19 Syndrome
2.
Inflammopharmacology ; 30(5): 1569-1596, 2022 Oct.
Article in English | MEDLINE | ID: covidwho-1877878

ABSTRACT

BACKGROUND: Melatonin is an indole hormone secreted primarily by the pineal gland that showing anti-oxidant, anti-inflammatory and anti-apoptotic capacity. It can play an important role in the pathophysiological mechanisms of various diseases. In this regard, different studies have shown that there is a relationship between Melatonin and Multiple Sclerosis (MS). MS is a chronic immune-mediated disease of the Central Nervous System. AIM: The objective of this review was to evaluate the mechanisms of action of melatonin on oxidative stress, inflammation and intestinal dysbiosis caused by MS, as well as its interaction with different hormones and factors that can influence the pathophysiology of the disease. RESULTS: Melatonin causes a significant increase in the levels of catalase, superoxide dismutase, glutathione peroxidase, glutathione and can counteract and inhibit the effects of the NLRP3 inflammasome, which would also be beneficial during SARS-CoV-2 infection. In addition, melatonin increases antimicrobial peptides, especially Reg3ß, which could be useful in controlling the microbiota. CONCLUSION: Melatonin could exert a beneficial effect in people suffering from MS, running as a promising candidate for the treatment of this disease. However, more research in human is needed to help understand the possible interaction between melatonin and certain sex hormones, such as estrogens, to know the potential therapeutic efficacy in both men and women.


Subject(s)
COVID-19 , Melatonin , Multiple Sclerosis , Adjuvants, Immunologic , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Antioxidants/pharmacology , Antioxidants/therapeutic use , Catalase/metabolism , Estrogens/pharmacology , Estrogens/therapeutic use , Female , Glutathione , Glutathione Peroxidase/metabolism , Humans , Inflammasomes , Male , Melatonin/pharmacology , Melatonin/therapeutic use , Multiple Sclerosis/drug therapy , NLR Family, Pyrin Domain-Containing 3 Protein , Oxidative Stress , SARS-CoV-2 , Superoxide Dismutase/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL